441 related articles for article (PubMed ID: 25345100)
1. Cystinosis: clinical presentation, pathogenesis and treatment.
Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
[TBL] [Abstract][Full Text] [Related]
2. The pathogenesis of cystinosis: mechanisms beyond cystine accumulation.
Wilmer MJ; Emma F; Levtchenko EN
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F905-16. PubMed ID: 20826575
[TBL] [Abstract][Full Text] [Related]
3. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
5. Early oral cysteamine therapy for nephropathic cystinosis.
Gahl WA
Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
[TBL] [Abstract][Full Text] [Related]
6. Nephropathic cystinosis: an update on genetic conditioning.
Topaloglu R
Pediatr Nephrol; 2021 Jun; 36(6):1347-1352. PubMed ID: 32564281
[TBL] [Abstract][Full Text] [Related]
7. CTNS mRNA molecular analysis revealed a novel mutation in a child with infantile nephropathic cystinosis: a case report.
Papizh S; Serzhanova V; Filatova A; Skoblov M; Tabakov V; van den Heuvel L; Levtchenko E; Prikhodina L
BMC Nephrol; 2019 Oct; 20(1):400. PubMed ID: 31672123
[TBL] [Abstract][Full Text] [Related]
8. Cystinosis: a review.
Elmonem MA; Veys KR; Soliman NA; van Dyck M; van den Heuvel LP; Levtchenko E
Orphanet J Rare Dis; 2016 Apr; 11():47. PubMed ID: 27102039
[TBL] [Abstract][Full Text] [Related]
9. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
10. [From gene to disease: cystinosis].
Levtchenko EN; Wilmer M; de Graaf-Hess AC; van den Heuvel LP; Blom H; Monnens LA
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):476-8. PubMed ID: 15042893
[TBL] [Abstract][Full Text] [Related]
11. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
[TBL] [Abstract][Full Text] [Related]
12. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
[TBL] [Abstract][Full Text] [Related]
14. Cystinosin is a Component of the Vacuolar H+-ATPase-Ragulator-Rag Complex Controlling Mammalian Target of Rapamycin Complex 1 Signaling.
Andrzejewska Z; Nevo N; Thomas L; Chhuon C; Bailleux A; Chauvet V; Courtoy PJ; Chol M; Guerrera IC; Antignac C
J Am Soc Nephrol; 2016 Jun; 27(6):1678-88. PubMed ID: 26449607
[TBL] [Abstract][Full Text] [Related]
15. Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis.
Hollywood JA; Kallingappa PK; Cheung PY; Martis RM; Sreebhavan S; 'Atiola RD; Chatterjee A; Buckels EJ; Matthews BG; Lewis PM; Davidson AJ
Am J Physiol Renal Physiol; 2022 Aug; 323(2):F156-F170. PubMed ID: 35695380
[TBL] [Abstract][Full Text] [Related]
16. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
18. [Cystinosis].
Watanabe H; Kamoshita S
Nihon Rinsho; 1992 Jul; 50(7):1593-8. PubMed ID: 1404889
[TBL] [Abstract][Full Text] [Related]
19. Extrarenal complications of cystinosis.
Topaloglu R
Pediatr Nephrol; 2024 Aug; 39(8):2283-2292. PubMed ID: 38127152
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
